Related references
Note: Only part of the references are listed.Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study
Elena Guerini Rocco et al.
DIAGNOSTICS (2022)
Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study
Bruna Cerbelli et al.
HISTOPATHOLOGY (2022)
PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis
Andrea Ambrosini-Spaltro et al.
VIRCHOWS ARCHIV (2022)
Prognostic role of immune microenvironment in pleural metastases from breast and lung adenocarcinomas
Georgia Karpathiou et al.
ANNALS OF TRANSLATIONAL MEDICINE (2022)
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)
Emma J. de Ruiter et al.
MODERN PATHOLOGY (2021)
Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity
Andy Karabajakian et al.
ORAL ONCOLOGY (2021)
The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis
Maroa Dridi et al.
CANCERS (2021)
Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer
Andreanne Gagne et al.
LUNG CANCER (2020)
Translating KEYNOTE-048 into practice recommendations for head and neck cancer
Petr Szturz et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology Concordance Among 3 Commonly Used and Commercially Available Antibodies
Henning Reis et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Jacob H. Rasmussen et al.
BRITISH JOURNAL OF CANCER (2019)
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study
Anne-Marie Boothman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays
Kristina Schwamborn et al.
VIRCHOWS ARCHIV (2019)
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations
Andreanne Gagne et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study
Francesca Giunchi et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
Anjelica Hodgson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs An Interclone Evaluation by Differently Trained Pathologists
Enrico Munari et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types
Chiyun Wang et al.
HUMAN PATHOLOGY (2018)
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Antonio Calles et al.
JOURNAL OF THORACIC ONCOLOGY (2015)